Welcome to our dedicated page for Coya Therapeutics SEC filings (Ticker: COYA), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Reading a clinical-stage biotech filing can feel like decoding a dense lab notebook. Coya Therapeutics’ 10-K alone weaves Treg science, trial data, and cash-runway math into over a hundred pages. If you are searching “Coya Therapeutics SEC filings explained simply” or wondering which executive bought shares before the next ALS data release, this page was built for you.
Stock Titan’s AI pinpoints the science and the numbers that matter. Our platform surfaces:
- Coya Therapeutics annual report 10-K simplified—see R&D expense trends and pipeline milestones without skimming footnotes.
- Coya Therapeutics quarterly earnings report 10-Q filing—quickly compare cash burn and trial costs quarter over quarter.
- Coya Therapeutics Form 4 insider transactions real-time—track executive stock moves as soon as they hit EDGAR.
- Coya Therapeutics 8-K material events explained—get plain-English summaries when new clinical data or FDA feedback lands.
- Coya Therapeutics proxy statement executive compensation—understand how milestone bonuses align with Treg therapy progress.
Every document is paired with an AI-powered summary, highlighting cash runway estimates, Treg therapy development stages, and key risk factors—ideal for investors asking “How do I analyze Coya Therapeutics’ earnings report filing?” or “Where can I find Coya Therapeutics insider trading Form 4 transactions?”. Real-time alerts, historical archives, and side-by-side form comparisons mean you spend minutes, not hours, extracting insight.
Whether you monitor Coya Therapeutics executive stock transactions Form 4 before Phase 2 data or need a concise view of collaborative revenue in the latest 10-Q, our AI turns complex immunology jargon into actionable clarity.
Coya Therapeutics (NASDAQ:COYA) filed a Form 8-K reporting the results of its June 26, 2025 Annual Meeting of Stockholders.
- Directors re-elected: Howard Berman, Ph.D. (5,821,649 for), Arun Swaminathan, Ph.D. (6,324,520 for), and Ann Lee, Ph.D. (5,779,312 for); broker non-votes totaled 4,096,866 shares.
- Auditor ratified: Weaver & Tidwell, L.L.P. was approved as independent registered public accounting firm for FY 2025 with 10,355,085 votes for (98.9%), 68,851 against, and 340 abstentions.
No additional proposals were presented and the filing discloses no material changes to operations, strategy, or governance.
FAQ
What is the current stock price of Coya Therapeutics (COYA)?
What is the market cap of Coya Therapeutics (COYA)?
What does Coya Therapeutics, Inc. specialize in?
What is the core technology behind Coya Therapeutics' therapies?
Which diseases does Coya Therapeutics aim to address?
What sets Coya Therapeutics apart from its competitors?
What challenges does Coya Therapeutics face as a clinical-stage company?
How does Coya Therapeutics generate revenue?
What is the significance of regulatory T cells (Tregs) in Coya Therapeutics’ research?
Is Coya Therapeutics involved in partnerships or collaborations?
